发明公开
EP1575494A2 ENGINEERING ABSORPTION OF THERAPEUTIC COMPOUNDS VIA COLONIC TRANSPORTERS 审中-公开
工程吸收KOLONTRANSPORTER的治疗性化合物

  • 专利标题: ENGINEERING ABSORPTION OF THERAPEUTIC COMPOUNDS VIA COLONIC TRANSPORTERS
  • 专利标题(中): 工程吸收KOLONTRANSPORTER的治疗性化合物
  • 申请号: EP03737554.0
    申请日: 2003-01-24
  • 公开(公告)号: EP1575494A2
    公开(公告)日: 2005-09-21
  • 发明人: ZERANGUE, NoaCUNDY, Kenneth, C.GALLOP, Mark, A.
  • 申请人: Xenoport, Inc.
  • 申请人地址: 3410 Central Expressway Santa Clara, CA 95051 US
  • 专利权人: Xenoport, Inc.
  • 当前专利权人: Xenoport, Inc.
  • 当前专利权人地址: 3410 Central Expressway Santa Clara, CA 95051 US
  • 代理机构: Goodfellow, Hugh Robin
  • 优先权: US351808P 20020124; US351291 20030123
  • 国际公布: WO2003065982 20030814
  • 主分类号: A61K6/00
  • IPC分类号: A61K6/00
ENGINEERING ABSORPTION OF THERAPEUTIC COMPOUNDS VIA COLONIC TRANSPORTERS
摘要:
Methods of modifying therapeutic compounds such as drugs to be substrates for active transporters expressed in epithelial cells lining the lumen of the human colon are disclosed. The transporters expressed in the human colon include the sodium dependent multi-vitamin transporter (SMVT), and monocarboxylate transporters 1 and 4 (MCT 1 and MCT 4). The modified compounds can themselves be pharmacologically active, or upon cleavage of a chemical moiety after uptake from the colon, can be metabolized to form a compound that is pharmacologically active (e.g., a prodrug). The modified compounds disclosed herein are suitable for use in extended release oral dosage forms, particularly those that release drug over periods of greater than about 2-4 hours following administration.
信息查询
0/0